A detailed history of Klingman & Associates, LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Klingman & Associates, LLC holds 2,906 shares of MRNA stock, worth $191,069. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,906
Previous 2,888 0.62%
Holding current value
$191,069
Previous $307,000 12.38%
% of portfolio
0.02%
Previous 0.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$101.21 - $166.61 $1,821 - $2,998
18 Added 0.62%
2,906 $345,000
Q1 2024

May 01, 2024

SELL
$85.37 - $115.44 $82,382 - $111,399
-965 Reduced 25.05%
2,888 $307,000
Q4 2023

Jan 29, 2024

BUY
$69.51 - $104.43 $267,822 - $402,368
3,853 New
3,853 $383,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $25.7B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Klingman & Associates, LLC Portfolio

Follow Klingman & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Klingman & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Klingman & Associates, LLC with notifications on news.